BERGEN, Norway, May 29, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and provided a business update. Highlights, including post period: Data Safety Monitoring Board review supported dose escalation in Ph 1b and initiation of Ph2a Site activation of Ph2a in US and Europe proceeding well Bemcentinib remains the leading selective AXL inhibitor in the clinic and was selected for inclusion in National Cancer Institute funded study in advanced NSCLC, led by the Mays Cancer Center at the University of Texas Health Science Center at San Antonio Financial position of NOK 117.3 million at 31 March – strengthened further with gross funding of NOK 138.9 million from warrants exercise in April 2024 Continued reduction of operating expenses from NOK 72.4 million in Q1 2023 to NOK 39.9 million in Q1 2024 Net cash flow of NOK -42.5 million Martin Olin, Chief Executive Officer of BerGenBio stated: "1L NSCLC STK11m patients are not currently eligible for targeted therapy and face a very poor ...